Compositions and methods for treatment of pouchitis

A method of treating pouchitis in a human, comprising:

• identifying a human having pouchitis;
• and
• rectally administering to said human a pharmaceutical composition, wherein said pharmaceutical composition comprises an antisense oligonucleotide that specifically hybridizes to and inhibits the activity of a human ICAM-1 mRNA, wherein said antisense oligonucleotide comprises from 16 to 20 phosphorothioate linked nucleosides that are each independently selected from 2′-deoxynucleosides and nucleosides comprising a 2′-F modified sugar moiety or a 2′-O-methoxyethyl modified sugar moiety, wherein said rectally administering reduces an occurrence of one or more clinical symptoms selected from a group consisting of stool frequency, rectal bleeding, fecal urgency, abdominal cramps, and fever, and wherein said rectally administering reduces said pouchitis.